Yung-Tuen Chiu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Yung-Tuen Chiu has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Abdullah Husain
State Key Laboratory of Liver Research, The University of Hong Kong
2 shared publications - Chee Wai Chua
Cancer Biology Group, Department of Anatomy and Departments of 2 Pathology and 3 Surgery, Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China
2 shared publications Hiu-Fung Yuen
Department of Anatomy, Laboratory Block, Faculty of Medicine,The University of Hong Kong, 21 Sassoon Road, Hong Kong SAR, China
2 shared publications- Irene Oi-Lin Ng
Department of Pathology, The University of Hong Kong, Hong Kong, China
2 shared publications Kwan Man
2 shared publicationsKwok-Wah Chan
Department of Anatomy, Laboratory Block, Faculty of Medicine,The University of Hong Kong, 21 Sassoon Road, Hong Kong SAR, China
2 shared publications
Latest Publications
- Open Access
- 13 January 2023
- Published by Wolters Kluwer Health in Hepatology
- Vol. 78 (5) , 1368-1383
Midline 1 interacting protein 1 promotes cancer metastasis through FOS-like 1-mediated matrix metalloproteinase 9 signaling in HCC
Background and Aims: Understanding the mechanisms of HCC progression and metastasis is crucial to improve early diagnosis and treatment. This study aimed to identify key molecular targets involved in HCC metastasis. Approach and Results: Using whole-transcriptome sequencing of patients’ HCCs, we identified and validated midline 1 interacting protein 1 (MID1IP1) as one of the most significantly upregulated genes in metastatic HCCs, suggesting its potential role in HCC metastasis. Clinicopathological correlation demonstrated that MID1IP1 upregulation significantly correlated with more aggressive tumor phenotypes and poorer patient overall survival rates. Functionally, overexpression of MID1IP1 significantly promoted the migratory and invasive abilities and enhanced the sphere-forming ability and expression of cancer stemness-related genes of HCC cells, whereas its stable knockdown abrogated these effects. Perturbation of MID1IP1 led to significant tumor shrinkage and reduced pulmonary metastases in an orthotopic liver injection mouse model and reduced pulmonary metastases in a tail-vein injection model in vivo. Mechanistically, SP1 transcriptional factor was found to be an upstream driver of MID1IP1 transcription. Furthermore, transcriptomic sequencing on MID1IP1-overexpressing HCC cells identified FOS-like 1 (FRA1) as a critical downstream mediator of MID1IP1. MID1IP1 upregulated FRA1 to subsequently promote its transcriptional activity and extracellular matrix degradation activity of matrix metalloproteinase MMP9, while knockdown of FRA1 effectively abolished the MID1IP1-induced migratory and invasive abilities. Conclusions: Our study identified MID1IP1 as a regulator in promoting FRA1-mediated-MMP9 signaling and demonstrated its role in HCC metastasis. Targeting MID1IP1-mediated FRA1 pathway may serve as a potential therapeutic strategy against HCC progression.
- 13 January 2023
- Published by Wolters Kluwer Health in Hepatology
- Vol. 78 (5) , 1368-1383
Open AccessMidline 1 interacting protein 1 promotes cancer metastasis through FOS-like 1-mediated matrix metalloproteinase 9 signaling in HCC
Background and Aims: Understanding the mechanisms of HCC progression and metastasis is crucial to improve early diagnosis and treatment. This study aimed to identify key molecular targets involved in HCC metastasis. Approach and Results: Using whole-transcriptome sequencing of patients’ HCCs, we identified and validated midline 1 interacting protein 1 (MID1IP1) as one of the most significantly upregulated genes in metastatic HCCs, suggesting its potential role in HCC metastasis. Clinicopathological correlation demonstrated that MID1IP1 upregulation significantly correlated with more aggressive tumor phenotypes and poorer patient overall survival rates. Functionally, overexpression of MID1IP1 significantly promoted the migratory and invasive abilities and enhanced the sphere-forming ability and expression of cancer stemness-related genes of HCC cells, whereas its stable knockdown abrogated these effects. Perturbation of MID1IP1 led to significant tumor shrinkage and reduced pulmonary metastases in an orthotopic liver injection mouse model and reduced pulmonary metastases in a tail-vein injection model in vivo. Mechanistically, SP1 transcriptional factor was found to be an upstream driver of MID1IP1 transcription. Furthermore, transcriptomic sequencing on MID1IP1-overexpressing HCC cells identified FOS-like 1 (FRA1) as a critical downstream mediator of MID1IP1. MID1IP1 upregulated FRA1 to subsequently promote its transcriptional activity and extracellular matrix degradation activity of matrix metalloproteinase MMP9, while knockdown of FRA1 effectively abolished the MID1IP1-induced migratory and invasive abilities. Conclusions: Our study identified MID1IP1 as a regulator in promoting FRA1-mediated-MMP9 signaling and demonstrated its role in HCC metastasis. Targeting MID1IP1-mediated FRA1 pathway may serve as a potential therapeutic strategy against HCC progression.
- Open Access
- 20 May 2022
- Published by Elsevier in Journal of Hepatology
- Vol. 77 (3) , 880-882
Reply to: ‘EFNA3 is a prognostic biomarker for the overall survival of patients with hepatocellular carcinoma’
- 20 May 2022
- Published by Elsevier in Journal of Hepatology
- Vol. 77 (3) , 880-882
Open AccessReply to: ‘EFNA3 is a prognostic biomarker for the overall survival of patients with hepatocellular carcinoma’